In light of the NSABP B51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?
Are there any subgroups that would still benefit from RNI?
Answer from: Radiation Oncologist at Academic Institution
B51 has the potential to be a practice-changing trial! I agree with much of what Dr. @Recht writes in his thoughtful summary and commentary.To briefly summarize eligibility, the trial enrolled women with clinically node-positive disease (cT1-3 N1), who received NAC and had a pathologic complete...
Comments
Radiation Oncologist at Community Health Network
Thank you for the wonderful summary and analysis.
Thank you for the wonderful summary and analysis.
Radiation Oncologist at Columbia University Medical Center/ New York Presbyterian / Hudson Valley Hospital
I agree. Thank you so much!
I agree. Thank you so much!
Radiation Oncologist at Northside Hospital
This was a great summary of the data by Dr. @Gerbe...
This was a great summary of the data by Dr. @Gerbe...
Answer from: Radiation Oncologist at Community Practice
For stage II patients with pCR in the node, I recommended pMRT or RNI specifically for triple-negative cases. In stage III (T3N1) scenarios with pCR, I recommend pMRT or RNI to all patients. Given this data, I'll need to reassess the standard treatment for these two subsets.
It's worth noting that ...
Comments
Radiation Oncologist at Stroger Hospital
If there is a CR, I see no purpose of PM RT unless...
If there is a CR, I see no purpose of PM RT unless...
Answer from: Radiation Oncologist at Academic Institution
Dr. @Recht's and @Gerber's write-ups above are noteworthy and thoughtful. As Dr. @Gerber notes, the majority of patients here (80%) had pathCR in the breast and nodes, suggesting that practitioners were preferentially enrolling patients they felt were at very low risk of RT omission. The inclusion o...
My thoughts exactly! But far more elegantly stated...
This is a very important trial in the era of de-es...
I agree with Dr. @Recht. Thank you